Bifirorm®
983 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Pharmaco-therapeutic group: MIBP-eubiotic
pharmachologic effect
Eubiotic. The strains of Enterococcus faecium and Bifidobacterium longum, which are part of the preparation, are natural symbiotic bacteria that inhabit the gastrointestinal tract. The drug has a normalizing effect on the quantitative and qualitative composition of the intestinal microflora. The action is due both to the direct direct effect of the components included in the preparation (high antagonistic activity against pathogenic and conditionally pathogenic microorganisms) and indirectly stimulated local intestinal immunity (activation of immunoglobulin A synthesis, induction of endogenous interferon synthesis).
Bifidobacterium longum has a high survival rate in the human intestine and a high growth rate. The inclusion of the pathogenic enterococcus Enterococcus faecium, which normally colonizes the small intestine, makes it possible to exert a positive effect on the state and digestive functions of not only the fat but also the small intestine, especially in the presence of fermentative dyspepsia and meteorism.
Indications
- diarrhea caused by acute and exacerbation of chronic gastroenteritis, rotavirus infection;
- antibiotic-associated diarrhea;
- traveler's diarrhea;
- in the treatment of acute intestinal infections;
- in the treatment of chronic gastrointestinal diseases such as colitis, irritable bowel syndrome and other gastrointestinal disorders of functional genesis;
- normalization of intestinal microflora, treatment and prevention of dysbacteriosis and maintenance of the immune system in children over 2 years old and adults;
- lactose intolerance;
- as part of a comprehensive standard eradication therapy in patients with Helicobacter pylori infection.
Composition
1 capsule "Bifiform" contains:
Active ingredients: Bifidobacterium longum (Bifidobacterium longum - at least 107 bacterial cells), Enterococcus faecium (Enterococcus faecium - at least 107 bacterial cells).
Excipients: gum, magnesium stearate, lactic sourdough, lactulose, anhydrous dextrose.
No customer reviews for the moment.
Dosage and Administration
In acute diarrhea, the drug must be taken 1 capsule 4 times a day until stool is normalized. Then the drug should be continued in a dose of 2-3 capsules per day until the complete disappearance of symptoms.
To normalize the intestinal microflora and support the immune system, the drug is prescribed in a dose of 2-3 capsules per day 10-21 days.
Patients with lactose intolerance are advised to take the drug 1 capsule 3 times a day.
When conducting eradication therapy, Bifiform prescribes 2 capsules 2 times a day for two weeks from the first day of eradication therapy.
Children from 2 years on 1 capsule 2-3 times a day. If the child cannot swallow the capsule, it is necessary to open and mix the contents with a small amount of liquid.
Adverse reactions
When used in recommended doses, according to established indications, no side effects have been identified.
Contraindications
- individual hypersensitivity to the drug.
Pregnancy and Lactation
The use of the drug Bifiform during pregnancy and lactation is considered safe, because the drug is not absorbed and does not have a systemic effect.
Special instructions
Precautions: do not exceed the maximum daily dose.
Influence on ability to drive motor transport and control mechanisms
The drug does not affect the ability to drive a car and control mechanisms.
Overdosage
Overdose symptoms not previously reported. In the case of a significant excess of the recommended doses, it is advisable medical observation.
- Brand name: Bifiform
- Active ingredient: Bifidobacterium longum enterococcus fezium
- Manufacturer: Pfizer Consumer Medicine Management
Studies and clinical trials of Bifirorm (Click to expand)
- F/A
7 other products in the same category:
arrow_upward